Form 4: Emergent BioSolutions Director Katkin Receives Stock Options and Restricted Stock Units

Director Keith Katkin receives stock options and restricted stock units from Emergent BioSolutions as part of annual compensation for board and committee service.

Summary

• Keith Katkin, a director at Emergent BioSolutions Inc., received an annual grant of 34,403 restricted stock units (RSUs) on April 30, 2025, under the company's Stock Incentive Plan.
• These RSUs will vest on the day prior to the one-year anniversary of the grant date, contingent upon Katkin remaining a board member.
• Each RSU represents the right to receive one share of Emergent BioSolutions common stock upon vesting.
• Katkin also received 15,824 stock options with an exercise price of $5.45, also vesting on the same date and subject to continued board membership.
• The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
• Following these transactions, Katkin beneficially owns 94,275 shares of common stock and 41,572 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice, indicating stable corporate governance and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting requirements incentivize continued service on the board.

Industry Context

Granting stock options and RSUs to board members is a common practice to align their interests with the long-term success of the company and its shareholders. This is a standard form 4 filing reflecting that practice.

Comparison to Industry Standards

• Stock option and RSU grants are a typical component of compensation packages for directors at publicly traded companies, including those in the biotechnology sector.
• Companies like Moderna, BioNTech, and Novavax also utilize stock-based compensation to incentivize their board members and align their interests with shareholders.
• The specific number of options and RSUs granted varies based on company size, performance, and industry benchmarks for director compensation.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align director interests with company performance.
• The grants do not have an immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Emergent BioSolutions, Director Compensation, Stock Options, Restricted Stock Units, RSUs, Keith Katkin, Board of Directors, Incentive Plan, Beneficial Ownership